Hot Sliver Companies To Watch For 2014

The Korea Times is reporting that�Apple� (NASDAQ: AAPL  ) has cut Samsung out of producing its next-generation A7 chip. The Mac maker continues to diversify its component supplier base away from Samsung. Apple has already begun moving display sourcing to�LG Display� (NYSE: LPL  ) . The A7 business is reportedly going to�Taiwan Semiconductor Manufacturing� (NYSE: TSM  ) and its 20-nanometer process. The transition could hurt Samsung, since it would be left with excess unused. Samsung has supposedly been trying to grow its business with�NVIDIA� (NASDAQ: NVDA  ) to mitigate the risk of losing some Apple business.

In the video below, Fool contributor Evan Niu, CFA, explains what it means for investors.

There's no doubt that Apple is at the center of technology's largest revolution ever, and that longtime shareholders have been handsomely rewarded with over 1,000% gains. However, there is a debate raging as to whether Apple remains a buy. The Motley Fool's senior technology analyst and managing bureau chief, Eric Bleeker, is prepared to fill you in on both reasons to buy and reasons to sell Apple, and what opportunities are left for the company (and your portfolio) going forward. To get instant access to his latest thinking on Apple, simply click here now.

Top 5 Financial Companies To Watch In Right Now: Acciona SA (ANA)

Acciona SA is a Spain-based holding company active in the construction and engineering industry. It is engaged in renewable energy, water services and infrastructure sectors.The Company operates through six business areas; Infrastructure involves the construction, engineering and transportation, as well as hospital concessions; Real Estate is active in the development of real estate properties and parking lot operations; Energy involves the generation, distribution and sale of energy; Transportation and Logistics Services provides integrated transport services for passengers and cargo; Environmental and Urban Services is engaged in activities related to services in the urban scope and environment protection, such as the execution of all types of activities in the water supply; Other Activities is engaged in the provision of services related to funds management and financial intermediation, as well as wine production, among others. Advisors' Opinion:

• [By Sarah Jones]

  Iberdrola SA (IBE), Spain�� biggest power company, fell 3.4 percent to 3.87 euros. Endesa SA (ELE) slumped 4.6 percent to 16 euros, while Acciona SA (ANA), which owns more than 4 gigawatts of wind farms in the country, tumbled 8.5 percent to 37.95 euros. Red Electrica Corp. slid 7.5 percent to 38.34 euros.

Hot Sliver Companies To Watch For 2014: Live Nation Entertainment Inc. (LYV)

Live Nation Entertainment, Inc. operates as a live entertainment company. The company operates through Concerts, Ticketing, Artist Nation, and Sponsorship & Advertising segments. The Concerts segment engages in the promotion of live music events in its owned and/or operated venues, and in rented third-party venues; operation and management of music venues; and production of music festivals. The Ticketing segment operates an agency business that sells tickets for its events and third-party clients across various live event categories through its Websites, telephone services, and ticket outlets. This segment provides ticketing services for arenas, stadiums, amphitheaters, music clubs, concert promoters, professional sports franchises and leagues, college sports teams, performing arts venues, museums, and theaters. The Artist Nation segment offers management services to music artists; sells merchandise associated with musical artists at live performances to retailers and dire ctly to consumers through the Internet; and provides other services to artists. The Sponsorship & Advertising segment offers online advertising services; and online sponsorship programs for corporate clients. As of December 31, 2012, the company owned, operated, or leased 93 entertainment venues and 100 other facilities in North America; and 22 entertainment venues and 82 other facilities internationally. The company was formerly known as Live Nation, Inc. and changed its name to Live Nation Entertainment, Inc. in January 2010. Live Nation Entertainment, Inc. was incorporated in 2005 and is headquartered in Beverly Hills, California.

Advisors' Opinion:

• [By Bloomberg]

  To spark a bidding contest for World Wrestling Entertainment Inc. (WWE), all Vince McMahon needs to do is wave a "for sale" sign. McMahon, 68, controls the voting power of the $2.3 billion company that's been entertaining spectators with staged fights for decades. The stock is at a record after WWE launched its own subscription streaming network and became the subject of takeover speculation. Should McMahon ever decide he's ready to sell, companies from Comcast Corp. (CMCSA) to Madison Square Garden Co. (MSG) may line up with offers, Albert Fried & Co. and National Alliance Capital Markets said. "What is McMahon's succession plan and who will he pass the keys of the kingdom to?" Robert Routh, an analyst at National Alliance, said in a phone interview. "WWE would be very attractive to many different types of buyers. What they've built can't be recreated. But without McMahon's blessing, it doesn't matter how much somebody is willing to pay for the company." The franchise that thrust Hulk Hogan and The Rock into stardom owns the television shows "Raw" and "Smackdown," which have a dedicated following and command high cable-TV ratings, Vertical Group said. The company, which is hosting its annual WrestleMania event in three weeks, will post its best revenue and profit growth in more than a decade next year, according to analysts' estimates compiled by Bloomberg. Stock Surge The stock has climbed 35 percent this month, in part because of takeover speculation, to close at $30.94 last week. WWE isn't in merger talks, Chief Financial Officer George Barrios said in an interview March 6. A representative for the Stamford, Connecticut-based company, declined to comment last week beyond Barrios' earlier statement. WWE's programs, which air on Comcast's USA and SyFy cable networks, may find a new home by the end of April, Barrios said. He said the company is in discussions on future domestic TV distribution with "multiple parties." It has held distribution tal

• [By Lisa Levin]

  Breaking news

  Weyerhaeuser Co (NYSE: WY) reported a 34% rise in its third-quarter profit. Weyerhaeuser's quarterly profit surged to $157 million, or $0.27 per share, from $117 million, or $0.22 per share, in the year-ago period. To read the full news, click here. Sorrento Therapeutics (NASDAQ: SRNE) announced the pricing of an underwritten public offering of 4,150,000 shares of common stock at an offering price of $7.25 per share. To read the full news, click here. Live Nation Entertainment (NYSE: LYV) has acquired Voodoo Music & Arts Experience, New Orleans' critically-acclaimed music festival. To read the full news, click here. B/E Aerospace (NASDAQ: BEAV) today announced that its Board of Directors has appointed Werner Lieberherr, who is currently President and Chief Operating Officer of B/E Aerospace, Inc., as co-Chief Executive Officer of B/E Aerospace, Inc. effective as of January 1, 2014. To read the full news, click here.

  Posted-In: JP Morgan US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets

Hot Sliver Companies To Watch For 2014: Sarepta Therapeutics Inc (SRPT)

Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., incorporated on July 22, 1980, biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company�� product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. The Company is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. The Company's program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). The Company initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.

The Company is also leveraging the capabilities of its RNA-based technology platforms to develop therapeutics for the treatment of infectious diseases. The Company's RNA-based drug programs are clinically evaluated for the treatment of DMD and have also demonstrated anti-viral activity in infectious diseases such as Ebola, Marburg and H1N1 influenza in certain animal models. The Company's lead product candidates are at various stages of development.

Duchenne Muscular Dystrophy Program

The Company's lead program is designed to address specific gene mutations that result in DMD by forcing the genetic machinery to skip over an adjacent contiguous piece of RNA and, thus, restore the ability of the cell to express a new, truncated but functional, dystrophin protein.

Eteplirsen is an antisense PMO-based therapeutic in clinical development for the treatment of individuals with DMD who have an error in the gene codi! ng for dystrophin that can be treated by skipping exon 51. Eteplirsen targets the frequent series of mutations that cause DMD. Eteplirsen has been granted orphan drug designation in the United States and European Union. In addition to the Company's lead product candidate, eteplirsen, the Company is actively pursues development of a product candidate that skips exon 45 through an IND-enabling collaboration.

Anti-Viral Programs

The Company is implementing its RNA-based technology platforms in its anti-viral programs for the development of therapeutics to treat viruses, such as Ebola, Marburg and influenza. The Company's arrangement with DoD supporting the development of the Company's Ebola and Marburg virus drug candidates provides funding for all clinical and licensure activities necessary to obtain approval of a New Drug Application (NDA), by the United States Food and Drug Administration (FDA), if DoD exercises all of its options under the arrangement. During the year ended December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and is exploring funding opportunities or partnerships with DHHS and industry collaborators to advance its development.

The Company's anti-viral therapeutic programs use the Company's translation suppression technology and applies its PMOplus chemistry backbone, an advanced generation of its base PMO chemistry backbone that selectively introduces positive backbone charges to improve selective interaction between the drug and its target. The Company's translation suppressing technology is based on Translation Suppressing Oligomers (TSOs), which are PMO-based compounds that stop or suppress the translation of a specific protein by binding to their specific target sequence in mRNA.

The Company is pursuing development and regulatory approval of its Ebola and Marburg hemorrhagic fever virus product candidates under the FDA's Animal Rule. The Company's lead product candidate against the Ebola virus infec! tion is A! VI-6002. For Marburg virus infection, the Company's lead product candidate has been AVI-6003. In February 2012, the Company announced that the Company received approval from the FDA to remove one of the two oligomers composing AVI-6003 and proceed with a single oligomer approach, AVI-7288, given that efficacy in non-human primates has been demonstrated to be attributable to this single oligomer. The Company is exploring the feasibility of alternate routes of administration of its Ebola and Marburg drug candidates, and at DoD's invitation, the Company is developing a proposal to be submitted for a study to demonstrates feasibility of the intramuscular route.

AVI-6002, which is a combination of AVI-7537 and AVI-7539, is designed for post-exposure prophylaxis after documented or suspected exposure to the Ebola virus. The Company is evaluating the feasibility of developing AVI-7537 as a single agent for the post-exposure prophylaxis after documented or suspected exposure to Ebola virus. AVI-6003, which is a combination of AVI-7287 and AVI-7288, is designed for post-exposure prophylaxis after documented or suspected exposure to Marburg virus. In February 2012, the Company announced that the Company received approval from the FDA to proceed with AVI-7288 as a single agent against Marburg virus infection. The Company intends to proceed with dosing AVI-7288 in the Phase I multiple ascending dose studies and in non-human primate studies.

Influenza Program

The Company's anti-viral therapeutic programs are also focused on the development of the Company's product candidates designed to treat pandemic influenza viruses. AVI-7100 is the Company's lead product candidate for the treatment of influenza and employs its PMOplus technology. In June 2011, the Company initiated dosing of AVI-7100 through intravenous infusion in single-ascending doses in up to 48 healthy adult volunteers. As of December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and are exp! loring fu! nding opportunities or partnerships to advance its development.

The Company has developed three new phosphorodiamidate-linked morpholino oligomers (PMO)-based chemistry platforms in addition to its original PMO-based technology. The Company's PMO-based molecules are designed to sterically block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this selective targeting, two distinct biologic mechanisms of action can be initiated: modulation of pre-mRNA splicing and inhibition of mRNA translation.

The Company competes with GlaxoSmithKline plc, Toyama Chemical, Alnylam Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corp., Isis Pharmaceuticals, Inc., Prosensa, and Santaris Pharma A/S.

Advisors' Opinion:

• [By Teresa Rivas]

  Sarepta Therapeutics (SRPT) and Prosensa Holding NV (RNA) were both big movers today, although in very different directions.

  At recent check, Prosensa was down 69%. Earlier today the company, partnered with GlaxoSmithKline (GSK), announced that the primary endpoint in its Phase 3 study of its Duchenne muscular dystrophy treatment Drisapersen was not met.

  In a randomized double-blind study of 186 boys over 48 weeks, the drug did not show statistically significant improvement in the 6 Minute Walking Distance (6MWD) test compared to a placebo.

  On a conference call, management said that it could take weeks, if not months to analyze the data, and thus could not offer guidance in regard to its next step would be.

  By contrast Sarepta was jumping 22% on the news, as it is developing the drug Eteplirsen as a rival treatment. Barron�� Andrew Bary correctly predicted last month that Prosensa�� loss would be Sarepta�� gain. Nonetheless, there was some chatter about potentially increased difficulty for Eteplirsen�� approval in the wake of the Drisapersen disappointment.

  Still, both Needham’s Chad Messer and Robert W. Baird’s Brian Skorney view the news as a bullish event.

  Messer writes “Although we concede some people, potentially including the FDA, may now be more skeptical of exon-skipping technology in general, we are confident in Etelpirsen’s efficacy based on the long-term consistency of the Phase IIb data.” He also believes that with Drisapersen’s removal, there is less risk to Etelpirsen’s market share position. He has a $57 price target on the stock.

  Skorney also notes that the news may not be all positive, given the possibility of caution from regulators, but writes “we believe the elimination of Prosensa as a potential competitor more than offsets any increase in risk to the fundamental thesis.” He has a $63 price target on the stock.

• [By Jake L'Ecuyer]

  Leading and Lagging Sectors
  Monday morning, the healthcare sector proved to be a source of strength for the market. Leading the sector was strength from Sarepta Therapeutics (NASDAQ: SRPT) and STAAR Surgical Company (NASDAQ: STAA). In trading on Monday, basic materials shares were relative laggards, down on the day by about 0.45 percent.

Hot Sliver Companies To Watch For 2014: Dole Food Company Inc(DOLE)

Dole Food Company, Inc. engages in sourcing, growing, processing, marketing, and distributing fresh fruits and vegetables, and food products to wholesale, retail, and institutional customers worldwide. It operates in three segments: Fresh Fruit, Fresh Vegetables, and Packaged Foods. The Fresh Fruit segment involves in growing and selling bananas under the DOLE brand name primarily in North America, Europe, and Asia; ripening and distributing DOLE and non-DOLE branded fresh produce in Europe; growing, sourcing, and selling fresh pineapples under the DOLE TROPICAL GOLD label; and exporting Chilean fruits, including grapes, apples, pears, stone fruits, and kiwifruits primarily to North America, Latin America, and Europe. The Fresh Vegetables segment engages in sourcing, harvesting, cooling, distributing, and marketing various fresh and fresh-cut vegetables, including iceberg lettuce, red and green leaf lettuce, romaine lettuce, butter lettuce, celery, cauliflower, broccoli, c arrots, Brussels sprouts, green onions, asparagus, snow peas, artichokes, and radishes, as well as fresh strawberries and raspberries. This segment also processes and markets value-added vegetable products, such as packaged salads and packaged fresh-cut vegetables. The Packaged Foods segment produces and markets canned pineapples, canned pineapple juice, fruit juice concentrate, fruit parfaits, snack foods, and frozen fruits, as well as fruits in plastic cups, jars, and pouches. Its principal customers include mass merchandisers and supermarkets. Dole Food Company, Inc. was founded in 1851 and is based in Westlake Village, California.

Advisors' Opinion:

• [By Rich Duprey]

  That's why seeing Dole Foods (NYSE: DOLE  ) lurch from a stock buyback program one day to suspending it weeks later so it can buy new ships instead, rattled investors and caused its stock to drop 10% so far.

Hot Sliver Companies To Watch For 2014: NiSource Inc (NI)

NiSource Inc. (NiSource), incorporated on March 29, 2000, is an energy holding company whose subsidiaries provide natural gas, electricity and other products and services to approximately 3.8 million customers located within a corridor that runs from the Gulf Coast through the Midwest to New England. NiSource operates in three business segments: Gas Distribution Operations; Gas Transmission and Storage Operations, and Electric Operations. NiSource�� principal subsidiaries include Columbia Energy Group (Columbia), a vertically-integrated natural gas distribution, transmission and storage holding company whose subsidiaries provide service to customers in the Midwest, the Mid-Atlantic and the Northeast; Northern Indiana Public Service Company (Northern Indiana), a vertically-integrated gas and electric company providing service to customers in northern Indiana, and Bay State Gas Company (Columbia of Massachusetts), a natural gas distribution company serving customers in Massachusetts.

NiSource Finance Corporation (NiSource Finance) is a 100% owned, consolidated finance subsidiary of NiSource. NiSource Finance engages in financing activities to raise funds for the business operations of NiSource and its subsidiaries.

Gas Distribution Operations

NiSource�� natural gas distribution operations serve more than 3.3 million customers in seven states and operate approximately 58 thousand miles of pipeline. Through its wholly owned subsidiary, Columbia, NiSource owns five distribution subsidiaries that provide natural gas to approximately 2.2 million residential, commercial and industrial customers in Ohio, Pennsylvania, Virginia, Kentucky, and Maryland. NiSource also distributes natural gas to approximately 795 thousand customers in northern Indiana. Additionally, NiSource�� subsidiary, Columbia Gas of Massachusetts, distributes natural gas to approximately 298 thousand customers in Massachusetts.

Gas Transmission and Storage Operations

NiSou! rce�� Gas Transmission and Storage Operations subsidiaries own and operate approximately 15,000 miles of pipeline and operate a natural gas storage system capable of storing approximately 639 billion cubic feet of natural gas. Through its subsidiaries, Columbia Gas Transmission L.L.C. (Columbia Transmission), Columbia Gulf Transmission Company (Columbia Gulf) and Crossroads Pipeline Company (Crossroads Pipeline), NiSource owns and operates an interstate pipeline network extending from the Gulf of Mexico to New York and the eastern seaboard. Together, these companies serve customers in 16 northeastern, mid-Atlantic, midwestern and southern states and the District of Columbia. NiSource Midstream Services is an unregulated business that is a provider of midstream services, including gathering, treating, conditioning, processing, compression and liquids handling, as well as managing mineral rights positions in the Marcellus and Utica shale areas.

The Gas Transmission and Storage Operations subsidiaries are also engaged in two joint ventures, Millennium Pipeline Company, L.L.C. (Millennium) and Hardy Storage Company, L.L.C. (Hardy Storage). Millennium Pipeline, which includes 252 miles of 30-inch-diameter pipe across New York�� Southern Tier and lower Hudson Valley, has the capability to transport up to 525,400 dekatherm per day of natural gas to markets along its route, as well as to the New York City markets through its pipeline interconnections. Millennium is jointly owned by affiliates of NiSource, DTE Energy and National Grid. Hardy Storage, which consists of underground natural gas storage facilities in West Virginia, has a working storage capacity of 12 billion cubic feet and the ability to deliver 176,000 dekatherm of natural gas per day. Hardy Storage is a joint venture of subsidiaries of Columbia Transmission and Piedmont Natural Gas Company, Inc. (Piedmont).

Electric Operations

NiSource generates, transmits and distributes electricity through its subsidia! ry Northe! rn Indiana Public Service Company (Northern Indiana) to approximately 458 thousand customers in 20 counties in the northern part of Indiana and engages in electric wholesale and transmission transactions. Northern Indiana operates three coal-fired electric generating stations. The three operating facilities have a net capability of 2,574 megawatts. Northern Indiana also owns and operates Sugar Creek, a Combined Cycle Gas Turbine (CCGT) plant with a 535 megawatts capacity rating, four gas-fired generating units located at Northern Indiana�� coal-fired electric generating stations with a net capability of 203 megawatts and two hydroelectric generating plants with a net capability of 10 megawatts. These facilities provide for a total system operating net capability of 3,322 megawatts. Northern Indiana�� transmission system, with voltages from 69,000 to 345,000 volts, consists of 2,797 circuit miles. Northern Indiana is interconnected with five neighboring electric utilities.

Advisors' Opinion:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on NiSource (NYSE: NI  ) , whose recent revenue and earnings are plotted below.

• [By guruek]

  According to GuruFocus Insider Data, these are the largest insider buys during the past week: Kimberly-Clark Corporation (KMB), Ecolab Inc. (ECL), Delta Air Lines Inc. (DAL), Green Mountain Coffee Roasters, Inc. (GMCR), and NiSource Inc. (NI).

• [By Lauren Pollock]

  NiSource Inc.(NI) said its fourth-quarter profit rose 13% as all three of the utility company’s segments posted revenue growth. But the top line missed estimates.

Hot Sliver Companies To Watch For 2014: Lenovo Group Ltd (LNVGY)

Lenovo Group Limited (Lenovo) is a personal technology company serving customers in more than 160 countries. The Company is a personal computer (PC) vendor. The Company develops, manufactures and markets technology products and services. Its product lines include Think-branded commercial PCs and Idea branded consumer PCs, as well as servers, workstations, and a family of mobile Internet devices, including tablets and smart phones. Lenovo operates seven research and development centers and more than 46 world-class labs, including research centers in Yamato, Japan; Beijing, Shanghai and Shenzhen, China; and Raleigh, North Carolina, the United States. The Company is also engaged in investment holding. It operates in three segments: China, emerging markets (excluding China) and mature markets. Lenovo offers a range of commercial desktops to businesses of all sizes.

The Company�� products include laptops, tablets, desktops, workstations and servers. In May 2010, it launched the LePhone smartphone in China. During the fiscal year ended March 31, 2011 (fiscal 2011), China accounted for 46.4% of the Company�� total sales. During fiscal 2011, Emerging Markets (excluding China) accounted for 17.9% of the Company�� total sales. During fiscal 2011, Mature Markets accounted for 35.7% of the Company�� total sales. Its brands include ThinkPad notebook, as well as products carrying the ThinkCentre, ThinkStation, ThinkServer, IdeaCentre and IdeaPad sub-brands.

Advisors' Opinion:

• [By Analyse360Degree]

  In contrast Samsung had a superb time, reporting a YoY growth of 32.0%, as its shipments increased from 8.5 million to 11.2 million in a years time. However, the most impressive growth was displayed by the fast growing Chinese manufacturer Lenovo (LNVGY). The company reported a stupendous growth of 224.3% in tablet shipments and presently accounts for 4.1% of the global tablet market, up from 1.3% in 1Q13. Lenovo has been taking its devices very seriously and seems to be hell-bent on making a mark on the space, clearly understood from its acquisition of Google (GOOG) owned Motorola.